Navigation Links
First Product from Rotman School's New Creative Destruction Lab
Date:2/25/2013

TORONTO, Feb. 25, 2013 /PRNewswire-USNewswire/ -- Last September the University of Toronto's Rotman School of Management quietly launched their new initiative for technology entrepreneurship, The Creative Destruction Lab.

Today, one of the ventures in the first cohort of this new initiative not so quietly has launched its first product, receiving attention from media including TechCrunch and Wired.

The MYO is the first product from Thalmic Labs. The device is an armband for gesture control that doesn't use cameras, but instead employs biosensors and accelerometers. Using Bluetooth, the armband connects wirelessly to other devices to enable user control based on their movements without directly touching the electronics. (Watch a demonstration here.)

"Thalmic quickly leveraged the Creative Destruction Lab and raised the majority of their seed capital from the Lab's G7 (coaching and investor group) including some of Canada's leading entrepreneurs like Daniel Debow , Senior Vice President of SalesForce.com, founder of Rypple and Rotman JD/MBA graduate, Tomi Poutanen , founder of Optimized Search Algorithms and Rotman MBA graduate, and Lee Lau , Director and Co-Founder of Alignvest Capital Management and founder of ATI, and their network," says Rotman Prof. Ajay Agrawal , Peter Munk Professor of Entrepreneurship and Academic Director of the Creative Destruction Lab.

To understand how devices such as the MYO could revolutionize how we interact with machines, you can read Rotman Prof. Joshua Gans ' article at Medium.

The Creative Destruction Lab at Rotman is a venture lab that leverages: the business sc
'/>"/>

SOURCE Rotman School of Management, University of Toronto
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
3. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
4. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
5. Webcor Builders Selected as the General Contractor for First Phase of LA BioMeds New Campus Master Plan
6. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
7. Tiger Woods Gives Exclusive First Interview Since POWERED by FUSE Announcement!
8. The Pharmabiotic Research Institute (PRI) is Preparing to Publish its First Works on the Therapeutic and Medicinal Potential of Probiotics
9. Eye Surgery Center of Michigan First in Southeast Michigan to Perform Bladeless Cataract Surgery Using New LenSx® Laser Technology
10. Amgen Announces 2012 First Quarter Dividend
11. Varian Medical Systems Schedules First Quarter FY2012 News Release and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... A new infographic compiles useful information about ... to learn how Apple’s new framework can change the ... ideal since Apple made Research Kit available ... framework for developing medical research apps that Apple announced ... to collect secure clinical data and communicate via subjects’ ...
(Date:4/16/2015)... 16, 2015 Avelas Biosciences, an in ... surgeries, announced today that it has initiated a Phase ... in women with primary, non-recurrent breast cancer undergoing surgery. ... the addition of Steven Chen , M.D., as ... label, dose escalation study will enroll up to 39 ...
(Date:4/16/2015)... British Columbia and MENLO PARK, ... Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), ... cancer therapies in new orphan drug indications, today announced ... been added as a clinical trial site for the ... with refractory glioblastoma multiforme (GBM), the most common and ...
(Date:4/16/2015)... 2015 Dana-Farber Cancer Institute and ... Resolution Bioscience, Inc. today announced the successful completion ... blood-based, clinic ready, Next Generation Sequencing (NGS) assay ... is the first to demonstrate the successful sequencing ... in blinded plasma samples and highlights the ability ...
Breaking Biology Technology:Infographic Illustrates Potential for Research Kit to Impact Clinical Research 2Infographic Illustrates Potential for Research Kit to Impact Clinical Research 3Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 2Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 3
... to the Advanced Performance of the A1 Series of ... , MELVILLE, N.Y., Dec. 15 Offering ... Nikon Instruments, Inc.,s ( www.nikoninstruments.com ) A1 series of ... software brings biological imaging to life. The software, ...
... Scientific,Corporation (NYSE: BSX ) today announced that ... Express(R) SD Renal Monorail(R),Premounted Stent System for use as ... lesions of the renal arteries. The,Express SD System ... renal arteries in the United States. It is ...
... 15 Cylene Pharmaceuticals today announced,the initiation of ... in,patients with carcinoid/neuroendocrine tumors (C/NET), which are malignant,cancers ... "Quarfloxin (CX-3543) is a ... in the abnormal nucleoli of cancer cells, thereby,selectively ...
Cached Biology Technology:Nikon Instruments A1 Confocal Laser Microscope Series With NIS-Elements C Software Delivers Fully Integrated Comprehensive Confocal Imaging Capabilities 2Nikon Instruments A1 Confocal Laser Microscope Series With NIS-Elements C Software Delivers Fully Integrated Comprehensive Confocal Imaging Capabilities 3FDA Approves Boston Scientific's Express(R) SD Renal Stent System 2FDA Approves Boston Scientific's Express(R) SD Renal Stent System 3FDA Approves Boston Scientific's Express(R) SD Renal Stent System 4Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors 2Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors 3
(Date:4/9/2015)... SAN JOSE, Calif. , April 9, 2015 /PRNewswire/ ... of human interface solutions, announced today that it will ... 2015 on Thursday, April 23, 2015, after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
(Date:4/2/2015)... , April 2, 2015 ... tests DERMALOG by far outperforms the strongest competitors, ... maintaining high accuracy, the system is capable of ... the speed proves up to be ten times ... than its runner-up performance.      (Photo: ...
(Date:4/2/2015)... , April 2, 2015 Fingerprint ... fingerprint sensor FPC1025 from the distributor World Peace Industrial ... during Q2 2015 although the major part of the ... will be used by smartphone manufacturers in ... is included in the communicated revenue guidance of + ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... and two collaborators have received a $3.4 million research ... of prostate cancer using MRI, or magnetic resonance imaging. ... two years from the American Recovery and Reinvestment Act ... of Health under an initiative to promote industry and ...
... A new internet-based tool for designing agricultural terraces ... optimize design by allowing rapid development of alternative layouts. ... Resource: Engineering & Technology for a Sustainable World , ... Engineering at the University of Missouri, introduces a web-based, ...
... species are not just discovered in exotic localeseven places ... plants and animals. Academy scientists recently named a new ... fishes distantly related to sharks, from the coast of ... the Eastern Pacific black ghostshark ( Hydrolagus melanophasma ), ...
Cached Biology News:Rutgers to collaborate in $3.4 million effort to improve prostate cancer identification using MRI 2Web-based innovation improves, eases agricultural terrace design 2New species of ghostshark from California and Baja California 2
... The binding specificity and signaling of ... known to be modified by alternative splicing--which ... GPCR SpliceArrays you can perform a classical ... detect the different alternatively spliced forms of ...
... color screen, without Camera • ... 8.0 mega pixel resolution. It is computer free ... image from large 5.6" TFT color liquid crystal ... to capture image for fluorescent gels, colorimetric gels, ...
... signaling of the members of the GPCR ... alternative splicing--which has important implications for drug ... a classical expression profiling and at the ... forms of the gene that are expressed ...
Mouse monoclonal antibody raised against a full length recombinant CSNK2A2. NCBI Entrez Gene ID = CSNK2A2...
Biology Products: